Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TR1 : Notification of Major Shareholding

10/13/2021 | 12:29pm EST

Arix Bioscience PLC (ARIX) TR1: Notification of Major Shareholding 13-Oct-2021 / 17:28 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 
i 
 
1a. Identity of the issuer or the underlying issuer of existing    ARIX BIOSCIENCE PLC 
shares to which voting rights are attached ii: 
1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate) 
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an "X") 
An acquisition or disposal of voting rights                                                               X 
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify) iii: 
3. Details of person subject to the notification obligation iv 
Name                                                               Takeda Ventures, Inc. 
                                                                   9625 Towne Centre Drive 
City and country of registered office (if applicable) 
                                                                   San Diego, CA 92121  USA 
4. Full name of shareholder(s) (if different from 3.) v 
Name 
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reached vi:          October 11, 2021 
6. Date on which issuer notified (DD/MM/YYYY):                     October 12, 2021 
7. Total positions of person(s) subject to the notification obligation 
                                                        % of voting rights 
                                % of voting rights      through financial     Total of both Total number of voting 
                                attached to shares      instruments           in % (8.A +   rights held in issuer (8.A 
                                (total of 8. A)         (total of 8.B 1 + 8.B 8.B)          + 8.B) vii 
                                                        2) 
Resulting situation on the date 
on which threshold was crossed  6,160,083               N/A                   6,160,083     6,160,083 
or reached 
Position of previous 
notification (if                5.4%                    N/A                   5.4% 
applicable) 
 
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii 
A: Voting rights attached to shares 
Class/type of            Number of voting rights ix        % of voting rights 
shares 
                         Direct            Indirect        Direct                                       Indirect 
ISIN code (if possible) 
                         (DTR5.1)           (DTR5.2.1)     (DTR5.1)                                     (DTR5.2.1) 
Ordinary Shares 
                         6,160,083                         4.8% 
GB00BD045074 
 
 
SUBTOTAL 8. A            6,160,083 
 
 
B 1: Financial Instruments according to DTR5.3.1R (1) (a) 
                                    Exercise/          Number of voting rights that may be acquired if 
Type of financial        Expiration Conversion Period  the instrument is                                % of voting 
instrument               date x     xi                                                                  rights 
                                                       exercised/converted. 
N/A 
 
 
                                    SUBTOTAL 8. B 1 
 
 
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) 
                                                  Physical or 
Type of financial      Expiration   Exercise/     cash                                                  % of voting 
instrument             date x       Conversion                 Number of voting rights                  rights 
                                    Period xi     Settlement 
                                                  xii 
N/A 
 
 
                                                  SUBTOTAL 
                                                  8.B.2 
 
 
 
9. Information in relation to the person subject to the notification obligation (please mark the 
applicable box with an "X") 
Person subject to the notification obligation is not controlled by any natural person or legal entity and 
does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) 
issuer xiii 
Full chain of controlled undertakings through which the voting rights and/or the 
financial instruments are effectively held starting with the ultimate controlling natural person or legal X 
entity (please add additional rows as necessary) xiv 
                 % of voting rights if it       % of voting rights through financial       Total of both if it equals or 
Name xv          equals or is higher than the   instruments if it equals or is higher than is higher than the notifiable 
                 notifiable threshold           the notifiable threshold                   threshold 
Takeda 
Pharmaceutical   100%                           ?                                           100% 
Company Limited 
Takeda 
Pharmaceuticals  27.3%                          ?                                           27.3% 
International AG 
Takeda 
Pharmaceuticals  100%                           ?                                           100% 
U.S.A. Inc. 
Takeda Ventures, 100%                           ?                                           100% 
Inc. 
 
 
10. In case of proxy voting, please identify: 
Name of the proxy holder                        none 
The number and % of voting rights held 
The date until which the voting rights will be 
held 
 
11. Additional information xvi 
 
 
                    9625 Towne Centre Drive 
Place of completion 
                    San Diego, CA 92121  USA 
Date of completion  October 12, 2021 

Notes

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

(MORE TO FOLLOW) Dow Jones Newswires

October 13, 2021 12:28 ET (16:28 GMT)

All news about ARIX BIOSCIENCE PLC
11/08Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
MT
10/29Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
MT
10/18ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
10/18Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
10/18Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
10/12ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
10/08ARIX BIOSCIENCE : Investee Pyxis Oncology Raises $167.2 Million in US IPO
MT
10/06FTSE 100 Closes Down on Fears of Rising Consumer Costs
DJ
10/06FTSE Drops, Sterling Expected to Gain on Prospect of Rate Rise
DJ
10/06ARIX BIOSCIENCE : Makes Interim CEO Permanent
MT
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 178 M 178 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 163 M 217 M 218 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 72,0%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | ARIX | GB00BD045071 | MarketScreener
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,32 GBX
Average target price 256,00 GBX
Spread / Average Target 19 368%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-38.36%223
INVESTOR AB (PUBL)48.89%73 421
CK HUTCHISON HOLDINGS LIMITED-4.71%25 681
GROUPE BRUXELLES LAMBERT SA19.73%16 577
HAL TRUST25.36%14 034
AB INDUSTRIVÄRDEN (PUBL)3.87%13 628